A universal MHCII technology platform to characterize antigen-specific CD4+ T cells

• DOI: 10.1016/j.crmeth.2022.100388
• Publication Date: 2023-01-13T15:56:26Z
• Authors: Rohit Vyasamneni; Victoria Kohler; Binisha Karki; Gauri Mahimkar; Ekaterina Esaulova; Jonathan McGee; Daniel Kallin; Joong Hyuk Sheen; Dewi Harjanto; Miles Kirsch; Asaf Poran; Jesse Dong; Lakshmi Srinivasan; Richard B. Gaynor; Meghan E. Bushway; John R. Srouji
• Keywords: Ex vivo; Immunophenotyping

CD4+ T cells are critical to the immune system and perform multiple functions; therefore, their identification characterization crucial better understanding in both health disease states. However, current methods rarely preserve ex vivo phenotype, thus limiting our of functions. Here we introduce a flexible, rapid, robust platform for cell identification. By combining MHCII allele purification, allele-independent peptide loading, multiplexed flow cytometry technologies, can enable high-throughput personalized identification, immunophenotyping, sorting. Using this combination with single-cell sorting multimodal analyses, identified characterized antigen-specific relevant COVID-19 cancer neoantigen immunotherapy. Overall, be used detect characterize across diseases, potential guide epitope design any disease-specific immunization strategy.